Darlene Dobkowski, MA

Enfortumab vedotin demonstrated a manageable safety profile and no unexpected toxicities in patients aged 80 years and older with urothelial carcinoma.

A retrospective study revealed that enfortumab vedotin did not produce excessive toxicity in older patients with urothelial carcinoma.

Most patients with mCRPC included in a real-world study did not undergo HRR testing at the time of diagnosis.

Experts at the 2024 San Antonio Breast Cancer Symposium discussed knowledge gaps in understanding how best to use ribociclib in treating patients with early breast cancer in the adjuvant setting.

Treatment with a 100-mg dose of bezuclastinib had a favorable safety and tolerability profile in patients with non-advanced systemic mastocytosis.

Patients with luminal B and HER2E breast cancer subtypes may have a greater PFS benefit with ribociclib plus endocrine therapy vs combination chemotherapy.

Glofitamab plus polatuzumab vedotin generated durable remissions in heavily pretreated, relapsed/refractory large B-cell lymphoma.

Revumenib plus decitabine/cedazuridine and venetoclax produced responses in relapsed/refractory acute myeloid leukemia.

Findings showed the potential impact of smoking on disease progression and survival in patients with myelodysplastic syndrome.

The risk of lymphedema was comparable for hypofractionated radiation therapy and normofractionated radiation therapy in early breast cancer.

AI models like GigaPath may pave the way for other predictive models in cancer, as it deciphers diagnoses and mutations in a more granular method.

Findings from the phase 2 RELATIVITY-104 study demonstrates a clinical benefit with the addition of relatlimab to nivolumab and chemotherapy.

Tumor infiltrating lymphocytes may have prognostic utility for OS outcomes with adjuvant chemotherapy and trastuzumab in early HER2-positive breast cancer.

Amivantamab plus chemotherapy yielded promising OS trends compared with chemotherapy in EGFR-mutant advanced NSCLC after disease progression on osimertinib.

Teclistamab plus daratumumab and lenalidomide had a manageable safety profile in patients with transplant-ineligible, newly diagnosed multiple myeloma.

Subcutaneous amivantamab was displayed noninferiority in terms of ORR vs intravenous administration in EGFR-mutated non–small cell lung cancer.

An artificial intelligence-based navigation tool may be used to call patients who previously missed their colonoscopy appointment with the goal that they will reschedule and attend the new appointment.

Darolutamide plus docetaxel/ADT was associated with a lower rate of hospitalization compared with placebo in metastatic hormone-sensitive prostate cancer.

The use of FOLFOXIRI plus bevacizumab increased in patients with metastatic colorectal cancer from 2013 to 2022, especially in patients 50 years of age or younger.

Treatment with ruxolitinib led to prolonged failure-free survival and improved disease control vs best available treatment in patients with either steroid-refractory or -dependent chronic graft-vs-host disease.

Autologous hematopoietic cell transplantation lowered relapse and progression rates and improved survival outcomes vs CAR T-cell therapy in patients with relapsed large B-cell lymphoma who experienced complete remission with interim treatment.

Idecabtagene vicleucel resulted in meaningful improvements in symptoms, functioning, overall health status, and health-related quality of life vs standard regimens in select patients with triple-class exposed relapsed/refractory multiple myeloma, according to updated data from the phase 3 KarMMa-3 trial.

Decisions regarding the intensification or de-escalation of treatment, particularly with immunotherapy and TKIs, for patients with renal cell carcinoma could be aided by circulating tumor DNA.

Treatment with zanzalintinib monotherapy produced antitumor activity and was well tolerated in patients with previously treated advanced clear cell renal cell carcinoma.

Immune checkpoint inhibitors have been associated with improved outcomes for patients with metastatic translocation renal cell carcinoma; however, novel therapies and therapeutic targets are needed for patients within this histologic subset.

Osimertinib plus chemotherapy reduced the risk of central nervous system disease progression or death vs osimertinib alone in patients with locally advanced or metastatic EGFR-positive non–small cell lung cancer who had brain metastases at baseline, according to data from the phase 3 FLAURA2 trial.

Treatment with the bispecific T-cell engager tarlatamab demonstrated antitumor activity and favorable safety outcomes in patients with previously treated small cell lung cancer.

Teclistamab continued to elicit deep and durable responses in patients with relapsed/refractory multiple myeloma, irrespective of being triple-class refractory, daratumumab-refractory, or refractory to last line of therapy.

Radium-223 was safe and did not preclude patients with metastatic castration-resistant prostate cancer from receiving subsequent life-prolonging therapies, including chemotherapy.

Study findings demonstrated that states that expanded Medicaid had improved survival rates in patients with pancreatic and gastric cancers, with greater improvements in Black patients for some analyses.